证券代码：603077 证券简称：和邦生物 公告编号：2025-033 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司关于控股股东 部分股份解除质押及部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 四川和邦生物科技股份有限公司（以下简称"公司"）控股股东四川和 邦投资集团有限公司（以下简称"和邦集团"）持有公司的股份数量为 计质押的股份数量为 1,069,000,000 股，占其持股总数比例为 54.44%，占公司 总股本比例为 12.10%。 ● 和邦集团及其一致行动人贺正刚先生合并持有公司股份总数为 及其一致行动人贺正刚先生合并质押的股份数量为 1,069,000,000 股，占其持股 总数比例为 44.98%，占公司总股本比例为 12.10%。 近日，公司收到和邦集团关于将其持有本公司的部分股份解除质押及部分股 份质押的通知，现将相关情况公告如下： 一、本次股份解质的基本情况 | 股东名称 | 四川和邦投资集团有限公司 | | | | | --- | -- ...

● 四川和邦生物科技股份有限公司（以下简称"公司"）控股股东四川和 邦投资集团有限公司（以下简称"和邦集团"）持有公司的股份数量为 1,963,779,103 股，占公司总股本比例 22.24%。截至本公告披露日，和邦集团累 计质押的股份数量为 1,069,000,000 股，占其持股总数比例为 54.44%，占公司 总股本比例为 12.10%。 ● 和邦集团及其一致行动人贺正刚先生合并持有公司股份总数为 2,376,411,103 股，占公司总股本比例的 26.91%。截至本公告披露日，和邦集团 及其一致行动人贺正刚先生合并质押的股份数量为 1,069,000,000 股，占其持股 总数比例为 44.98%，占公司总股本比例为 12.10%。 | 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-033 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司关于控股股东 部分股份解除质押及部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、 ...

Core Viewpoint - The announcement by Hebang Bio to suspend its 10GW N-type ultra-high-efficiency monocrystalline silicon wafer project reflects a significant strategic adjustment in response to the challenges faced by the photovoltaic industry, including overcapacity and declining profit margins [1][2][3]. Company Summary - Hebang Bio has faced difficulties in advancing its photovoltaic project, with only 13.37% of the budgeted investment completed by the end of 2024, indicating poor project management and fund utilization [2]. - The company has drastically reduced its research and development personnel from 39 in 2023 to just 1, and cut R&D spending from 13.43 million yuan to 2.49 million yuan, as it shifts focus away from photovoltaic and glass projects [2][3]. - The photovoltaic business incurred a loss of 120 million yuan in 2024, with revenues from the 10GW project amounting to 56.04 million yuan and a net profit loss of 163.54 million yuan [2]. Industry Summary - The photovoltaic industry is experiencing a significant shakeout, with many companies retracting from their investments due to overcapacity and intense price competition, leading to a decline in production utilization rates [4][5]. - Other companies, such as Huangshi Group and Madi Technology, have also halted their photovoltaic projects or divested their solar subsidiaries, highlighting the broader trend of strategic reevaluation within the industry [4]. - The current environment serves as a warning to new entrants in the photovoltaic sector, emphasizing the importance of respecting industry dynamics and building internal competitive strengths to survive in the long term [5].

Core Viewpoint - The company, Sichuan Hebang Biotechnology Co., Ltd., is actively responding to regulatory inquiries regarding its 2024 annual report, particularly focusing on its mining operations and financial disclosures related to its mineral resources [1][2]. Mining Operations - The company holds a total of 40 mining rights, including 34 exploration rights and 6 mining rights, with an investment of approximately 620 million yuan for acquiring these rights [1][2]. - The mining sector has become a core contributor to the company's operating profits, with an expected profit contribution of 250 million yuan from phosphate rock sales in 2024 [1][2]. - The company employs a phased investment and rolling development strategy in its mining operations to manage risks and ensure cash flow [1][2]. Financial Performance - The company reported a total operating income of 8.547 billion yuan in 2024, a decrease of 3.13% year-on-year, with a net profit of 31 million yuan, down 97.55% from the previous year [1][12]. - The phosphate and salt mines have generated significant revenue, with phosphate sales expected to increase as construction projects are completed [5][12]. Investment Strategy - The company is strategically expanding into the mining sector, aligning with macroeconomic policies and market conditions, while leveraging its existing resources and personnel expertise [9][10]. - The company has established a robust management structure and has recruited over 180 new employees in the mining sector since 2024, enhancing its operational capabilities [8][9]. Risk Management - The company utilizes a joint venture model for overseas mining projects to mitigate risks and ensure compliance with local regulations [10][11]. - A comprehensive risk control framework is in place for both domestic and international mining operations, focusing on environmental protection, safety, and regulatory compliance [10][11]. Sales and Revenue Breakdown - The company has achieved significant sales in its mining operations, with phosphate and salt mines contributing to the majority of its revenue [5][12]. - The sales model primarily involves internal sales within the group, with a high collection rate of 90% on receivables [5][12].

首创证券股份有限公司 关于上海证券交易所对四川和邦生物科技 股份有限公司 2024 年年度报告的信息披露监管问询函的 回复 保荐机构(主承销商) 创证券股份有限公 . SEC 2 问题 5: 关于在建工程。年报显示，公司在建工程期末余额 23.54 亿元，同 比增长 100.6%,本期购建固定资产、无形资产和其他长期资产支付的现金 11.16 亿元,应付票据期末余额 6.69亿元,同比增长 100.90%,系报告期内开立票据 支付材料、工程款增加所致。光伏项目方面,8GW 光伏封装材料及制品项目总 预算 30 亿元,本年度在建工程增加金额为 6.29 亿元,累计投入占预算比例仅从 2023 年末的 75.43%增长为 85.12%；半年报显示，10GWN+型超高效单晶太阳 能硅片项目工程累计投入占预算比例为 13.37%，公司称鉴于行业产能过剩将暂 停在光伏组件项目的投入，而年报未披露相关数据。 请公司补充披露:(1)结合 8GW 光伏封装材料及制品项目具体内容、建设 周期、预计完工期限、转固金额等,说明本期投资金额与累计投入占比不匹配 的原因及合理性,并结合项目建设规模、进度及市场情况、价格变化等说明本 期 ...

| 四川华信(集团)会计师事务所 | 地址：成都市洗面桥街 18 号金茂礼都南 28 楼 | | --- | --- | | （特殊普通合伙） | 电话：（028）85560449 传真：（028）85560449 | | | 邮编： 610041 | | SI CHUAN HUA XIN (GROUP) CPA (LLP) | 电邮： schxzhb@hxcpa.com.cn | 四川华信（集团）会计师事务所（特殊普通合伙） 关于上海证券交易所对四川和邦生物科技股份有限公司 2024 年年度报告的信息披露监管问询函的回复 川华信综 A（2025）第 0017 号 目录： 1、四川华信（集团）会计师事务所（特殊普通合伙）关于上海证券交易所对 四川和邦生物科技股份有限公司 2024 年年度报告的信息披露监管问询函 的回复 1 四川华信（集团）会计师事务所（特殊普通合伙） 关于上海证券交易所对四川和邦生物科技股份有限公司 公司回复： 2024 年年度报告的信息披露监管问询函的回复 川华信综 A（2025）第 0017 号 上海证券交易所： 我所作为四川和邦生物科技股份有限公司（以下简称 "和邦生物"或"公司"） ...

| 证券代码：603077 | 证券简称：和邦生物 | 公告编号：2025-032 | | --- | --- | --- | | 债券代码：113691 | 债券简称：和邦转债 | | 四川和邦生物科技股份有限公司 关于上海证券交易所《关于四川和邦生物科技股份有 限公司 2024 年年度报告的信息披露监管问询函》的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川和邦生物科技股份有限公司（以下简称"公司"）于近日收到上海证券 交易所上市公司监管一部下发的《关于四川和邦生物科技股份有限公司 2024 年 年度报告的信息披露监管问询函》（上证公函【2025】0869 号）（以下简称"《问 询函》"）。公司对《问询函》高度重视，积极组织相关各方对《问询函》所提 问题进行认真核查，现就相关问题回复并公告如下： 一、关于矿业情况。年报披露，公司矿产品（包含盐矿和磷矿）营业收入 3.92 亿元，合计利润贡献超 1.89 亿元，为本期主要利润来源。截至报告披露日， 公司通过自有、投资、合作等方式，获得可开发的矿权共计 39 ...

Core Viewpoint - The development of a "4+N" industrial project framework in Guang'an aims to establish a billion-level green chemical industry cluster, led by four major projects with a total investment exceeding 50 billion yuan, generating an annual output value of over 100 billion yuan and tax revenue nearing 10 billion yuan upon completion [1] Group 1: Industrial Development - The four major projects, including Hebang, Lier, Chengxin, and Jiuyuan, are expected to drive the growth of multiple billion-level or near-billion-level projects [1] - Guang'an has set a goal to create a trillion-level green chemical industry cluster, transitioning from a focus on key industrial chain collaboration to becoming a primary carrier for industrial chain scale enhancement [1] Group 2: Technological Innovation - Companies in Guang'an are implementing technological upgrades to achieve green development, with projects like the second phase of Jingu Environmental Protection converting kitchen waste oil into biodiesel [2][3] - Guang'an Economic Development Zone collaborates with universities to support the establishment of R&D centers, resulting in 51 invention patents and 13 industry-leading products [3] Group 3: Project Management and Progress - A rapid feedback mechanism, including daily progress meetings, is employed to address production challenges and ensure timely project completion [4] - The Guang'an Economic Development Zone has implemented a multi-faceted approach to enhance project quality and efficiency, including a three-party joint office model for problem-solving [4] Group 4: Service and Infrastructure Support - Guang'an Economic Development Zone acts as a "chief service officer" for enterprises, addressing challenges such as power supply issues for projects like the Jatai Haifu Silicon-based Nano Materials project [5][6] - Infrastructure improvements in the New Bridge Chemical Park, including wastewater treatment facilities and transportation networks, have significantly enhanced the park's operational capabilities [6]

Core Insights - The report maintains a "recommended" rating for the agricultural chemical industry, highlighting the recovery potential in the pesticide market due to rising glyphosate prices [1][8] - Glyphosate prices have shown a significant recovery, with the raw material price reaching 24,800 CNY per ton as of July 1, 2025, an increase of 1,800 CNY per ton since early April [6][8] Industry Performance - The basic chemical industry has outperformed the CSI 300 index over various time frames, with a 1-month performance of 5.0%, 3-month performance of 3.2%, and a 12-month performance of 16.4% compared to the CSI 300's 2.7%, 1.5%, and 13.6% respectively [4] Investment Highlights - The glyphosate industry is experiencing inventory depletion and demand recovery, leading to a price rebound from its bottom. As of June 27, 2025, glyphosate industry inventory was 40,000 tons, down 43,000 tons since early April [6] - The global largest glyphosate producer, Bayer, faces potential bankruptcy due to ongoing lawsuits related to its glyphosate product "Roundup," which could benefit domestic competitors in the glyphosate market [7] Company Focus - Key companies in the glyphosate sector include: - Jiangshan Chemical, with a production capacity of 70,000 tons/year [9] - Xingfa Group, the leading domestic glyphosate producer with a capacity of 230,000 tons/year [9] - Xin'an Chemical, with a capacity of 80,000 tons/year [10] - Yangnong Chemical, a major player with a capacity of 30,000 tons/year [10] - Guoxin Co., with a capacity of 20,000 tons/year [10] - Hebang Bio, with a capacity of 50,000 tons/year [10] - Lier Chemical, with a capacity of 18,500 tons/year [10] - Limin Co., with a capacity of 5,000 tons of glyphosate and 2,000 tons of refined glyphosate [10] Earnings Forecast - The report provides earnings per share (EPS) estimates for key companies, indicating potential growth in profitability: - Jiangshan Chemical: EPS of 1.10 CNY in 2025E [11] - Xingfa Group: EPS of 1.85 CNY in 2025E [11] - Yangnong Chemical: EPS of 3.44 CNY in 2025E [11] - Guoxin Co.: EPS of 1.12 CNY in 2025E [11] - Lier Chemical: EPS of 0.53 CNY in 2025E [11] - Limin Co.: EPS of 1.05 CNY in 2025E [11]

Summary of Key Points Core Viewpoint - The company Sichuan Hebang Biological Technology Co., Ltd. has announced the provision of guarantees for its subsidiaries, Sichuan Wujun Photovoltaic Co., Ltd. and Wujun Chongqing Photovoltaic Co., Ltd., totaling RMB 33.4 million, which aligns with its strategic financial management and support for subsidiary projects [1][2][6]. Group 1: Guarantee Details - The total guarantee amount for Sichuan Wujun Photovoltaic Co., Ltd. is RMB 134 million, with a current guarantee balance of RMB 384 million [1][2]. - The total guarantee amount for Wujun Chongqing Photovoltaic Co., Ltd. is RMB 200 million, with a current guarantee balance of RMB 1,197.2065 million [1][2]. - Both guarantees are structured as joint liability guarantees, with no counter-guarantees in place [2][6]. Group 2: Internal Decision-Making Process - The company’s board of directors approved the guarantee provision during a meeting held on April 28, 2025, with a total authorized guarantee limit of RMB 6 billion for subsidiaries [2][6]. - The company has set specific limits for guarantees based on the subsidiaries' debt-to-asset ratios, with a maximum of RMB 1.2 billion for those above 70% and RMB 4.8 billion for those below [2][6]. Group 3: Financial Overview of Guaranteed Entities - Sichuan Wujun Photovoltaic Co., Ltd. has total assets of RMB 3.1 billion and a net profit of RMB -25.624 million for the first quarter of 2025 [3][5]. - Wujun Chongqing Photovoltaic Co., Ltd. is a wholly-owned subsidiary of Sichuan Wujun, with a registered capital of RMB 100 million and a focus on solar energy services and photovoltaic equipment manufacturing [3][4]. Group 4: Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary to support the subsidiaries' ongoing projects and align with the company's overall strategic interests [6]. - The company maintains control over the subsidiaries' operations and finances, which mitigates the associated risks of the guarantees [6]. Group 5: Cumulative Guarantee Situation - As of June 30, 2025, the total external guarantees provided by the company and its subsidiaries amount to RMB 8.049 billion, representing 43.21% of the company's latest audited net assets [6]. - There are no overdue guarantees or guarantees provided to controlling shareholders or related parties [6].